Analysis of the expression of toll-like receptors 2 and 4 and cytokine production during experimental leishmania chagasi infection

Memorias do Instituto Oswaldo Cruz

Volumn 106, Issue 5, 2011, Pages 573-583

  Cezário, Glaucia Aparecida Gomes ^a   de Oliveira, Larissa Ragozo Cardoso ^a   Peresi, Eliana ^a   Nicolete, Vanessa Cristina ^a   Polettini, Jossimara ^b   de Lima, Carlos Roberto Gonçalves ^a   Gatto, Mariana ^a   Calvi, Sueli Aparecida ^a  

^a Doenças Tropicais   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Cytokines; Leishmania chagasi; TLR2; TLR4

Indexed keywords

LEISHMANIA DONOVANI CHAGASI; MUS;

EID: 80052777566     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762011000500010     Document Type: Article

References (59)

1. Agnello D, Lankford CSR, Bream J, Morinobu A, Gadina M, Shea JJO, Frucht DM 2003. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol 23: 147-161.
2. + cells in nonhealing Leishmania major infection. J Immunol 183: 4619-4627.
3. Ansari NA, Saluja S, Salotra P 2006. Elevated levels of interferongamma, interleukin-10 and interleukin-6 during active disease in Indian Kala azar. Clin Immunol 119: 339-345.
4. Bacellar O, Brodskyn C, Guerreiro J, Barral-Netto M, Costa CH, Coffman RL, Johnson WD, Carvalho EM 1996. Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. J Infect Dis 173: 1515-1518.
5. Bacellar O, Faria D, Nascimento M, Cardoso TM, Gollob KJ, Dutra WO, Scott P, Carvalho EM 2009. IL-17 production in patients with American cutaneous leishmaniasis. J Infect Dis 200: 75-78.
6. Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, Teixeira R, Johnson WD Jr 1986. New perspectives on a subclinical form visceral leishmaniasis. J Infec Dis 154: 1003-1011.
7. Barral A, Carvalho EM, Badaro R, Barral-Neto M 1986. Suppression of lymphocyte proliferative responses by sera from patients with American visceral leishmaniasis. Am J Trop Med Hyg 35: 735-742.
8. Becker I, Salaiza N, Aguirre M, Delgado J, Carrillo-Carrasco N, Kobeh LG, Ruiz A, Cervantes R, Torres AP, Cabrera N, González A, Maldonado C, Isibasi A 2003. Leishmania lipophosphoglycan (LPG) activates NK cells through Toll-like receptor 2. Mol Biochem Parasitol 130: 65-74.
9. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, Sacks DL 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194: 1497-1506.
10. + regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
11. Belosevic M, Finbloom DS, Van Der Meide, Slayter MV, Nacy CA 1989. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J Immunol 143: 266-274.
12. Bodgan C, Moll H, Solbach W, Röllinghoff M 1990. Tumor necrosis factor-α in combination with interferon-γ, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur J Immunol 20: 1131-1135.
13. Bradley JR 2008. TNF-mediated inflammatory disease. J Pathol 214: 149-160.
14. Buffet PA, Sulahian A, Garin YJF, Nassar N, Derouin F 1995. Culture microtitration: sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother 39: 2167-2168.
15. Carvalho EM, Bacellar O, Barral A, Badaro R, Johnson Jr WD 1989. Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Invest 83: 860-864.
16. Cillari E, Vitale G, Arcolco F, Agostino PD, Mocciaro C, Gambino G, Malta R, Stassi G, Giordano C, Milano S 1995. In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine 7: 740-745.
17. Cummings HE, Tuladhar R, Satoskar AR 2010. Cytokines and their STATs in cutaneous and visceral leishmaniasis. J Biomed Biotechonol 2010: 1-6.
18. Cunningham AC 2002. Parasitic adaptive mechanisms in infection by leishmania. Exp Mol Pathol 72: 132-141.
19. de Veer MJ, Curtis JM, Baldwin TM, DiDonato JA, Sexton A, McConville MJ, Handman E, Schofield L 2003. MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling. Eur J Immunol 33: 2822-2831.
20. Desjeux P 2001. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 95: 239-243.
21. Dong C 2008. Th17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8: 337-348.
22. Dye C 1996. The logic of visceral leishmaniasis control. Am J Trop Med Hyg 55: 125-130.
23. Fenech MF, Dunaiski V, Osborne Y, Morley AA 1991. The cytokinesis-block micronucleus assay as a biological dosimeter in spleen and peripheral blood lymphocytes of the mouse following acute whole-body irradiation. Mutat Res 263: 119-126.
24. Flandin JF, Chano F, Descoteaux A 2006. RNA interference reveals a role for TLR-2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-gamma - primed macrophages. Eur J Immunol 36: 411-420.
25. Flo TH, Halaas O, Torp S, Ryan L, Lien E, Dybdahl B, Sundan A, Espevik T 2001. Differential expression of Toll-like receptor 2 in human cells. J Leukoc Biol 69: 474-481.
26. Gantt KR, Goldman TL, McCormick ML, Miller MA, Jeronimo SMB, Nascimento ET, Britigan BE, Wilson ME 2001. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J Immunol 167: 893-901.
27. Gantt KR, Schultz-Cherry S, Rodriguez N, Jeronimo SMB, Nascimento ET, Goldman TL, Recker TJ, Miller MA, Wilson ME 2003. Activation of TGF-β by Leishmania chagasi: importance for parasite survival in macrophages. J Immunol 170: 2613-2620.
28. Ghalib HW, Whittle JA, Kubin M, Hashim FA, el-Hassan AM, Grabstein KH, Trinchieri G, Reed SG 1995. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol 154: 4623-4629.
29. Goto H, Prianti MG 2009. Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 5: 241-246.
30. Green LC, Wagner DA, Glogowski J 1982. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 126: 131-138.
31. Guedes PMM, Gutierrez FRS, Maia FL, Milanezi CM, Silva GK, Pavanelli WR, Silva JS 2010. IL-17 produced during Trypanosoma cruzi infection plays a central role in regulation parasite-induced myocarditis. PloS Negl Trop Dis 4: e604.
32. Hernandez-Pando R, Orozco H, Arriaga K, Sampieri A, Larriva-Sahd J, Madrid-Marina V 1997. Analysis of the local kinetics and localization of interleukin-1 alpha, tumour necrosis factor-alpha and transforming growth factor-beta during the course of experimental pulmonary tuberculosis. Immunol 90: 607-617.
33. Kaye PM, Svensson M, Ato M, Maroof A, Polley R, Stager S, Zubairi S, Engwerda CR 2004. The immunopathology of experimental visceral leishmaniasis. Immunol Rev 201: 239-253.
34. Kenney RT, Sacks DL, Gam AA, Murray HW, Sundar S 1998. Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis 177: 815-818.
35. Kostka SL, Dinges S, Griewank K, Iwakura Y, Udey MC 2009. IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J Immunol 182: 3039-3046.
36. Kropf P, Freudenberg MA, Modolell M, Price HP, Herath S, Antoniazi S, Galanos C, Smith DF, Müller I 2004. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immun 72: 1920-1928.
37. Kumar R, Pai K, Sundar S 2001. Reactive oxygen intermediates, nitrite and IFN-gamma in Indian visceral leishmaniasis. Clin Exp Immunol 124: 262-265.
38. Li J, Hunter CA, Farrell JP 1999. Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol 162: 974-979.
39. Liew FY, Li Y, Millott S 1990. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 145: 4306-4310.
40. Maier T, Güell M, Serrano L 2009. Correlation of mRNA and protein complex biological samples. FEBS Lett 583: 3966-3973.
41. Medzhitov R 2007. Recognition of microorganisms and activation of the immune response. Nature 449: 819-826.
42. Mishra BB, Gundra UM, Teale JM 2008. Expression and distribution of Toll-Like receptors 11-13 in the brain during murine neurocysticercosis. J Neuroinflammation 5: 53.
43. + (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 204: 805-817.
44. Paun A, Bankoti R, Joshi T, Pitha PM, Stäger S 2011. Critical role of IRF-5 in the development of T helper 1 responses to Leishmania donovani infection. PLoS Pathog 7: e1001246.
45. Pinelli E, Gonzalo RM, Boog CJ, Rutten VP, Gebhard D, del Real G, Ruitenberg J 1995. Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner. Eur J Immunol 25: 1594-1600.
46. Ray M, Gam AA, Boykins RA 2000. Inhibition of interferon-γ signaling by Leishmania donovani. J Infect Dis 181: 1121-1128.
47. Ribeiro de Jesus A, Luna T, Pacheco de Almeida R, Machado PR, Carvalho EM 2008. Pentoxifylline down modulate in vitro T cell responses and attenuate pathology in Leishmania and HTLV-I infections. Int Immunopharmacol 8: 1344-1353.
48. Robak T, Gladalska A, Stepien H 1998. The tumor necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 9: 145-154.
49. Schleicher U, Liese J, Knippertz I, Kurzmann C, Hesse A, Heit A, Fischer JAA, Weiss S, Kalinke U, Kunz S, Bodgan C 2007. NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12 but is independent of plsmacytoid DCs. J Exp Med 204: 893-906.
50. Sharma U, Singh S 2009. Immunobiology of leishmaniasis. Indian J Exp Biol 47: 412-423.
51. Silvestre R, Silva AM, Cordeiro-da-Silva A, Ouaissi A 2009. The contribution of Toll-like receptor 2 to the innate recognition of a Leishmania infantum silent information regulator 2 protein. Immunol 128: 484-499.
52. Suffia IJ, Reckling SKR, Piccirillo CA, Goldzmid RS, Belkaid Y 2006. Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med 203: 777-788.
53. Tesmer LA, Lundy SK, Sarkar S, Fox DA 2008. Th17 cells in human disease. Immunol Rev 223: 87-113.
54. Theodos CM, Povinelli L, Molina R, Sherry B, Titus RG 1991. Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo. Infect Immun 59: 2839-2842.
55. Tuon FF, Amato VS, Bacha HA, Almusawi T, Duarte MI, Neto VA 2008. Toll-like receptors and leishmaniasis. Infect Immun 76: 866-872.
56. Vanden ES, Goriely S, De Wit D, Goldman M, Willens F 2006. Preferencial production of the IL-12 (p40)/IL-23(p19) heterodimer by dendritic cells from human newborns. Eur J Immunol 36: 21-26.
57. Verma S, Kumar R, Katara GK, Singh LC, Negi NS, Ramesh V, Salotra P 2010. Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. PLoS One 5: e10107.
58. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ 2004. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 202: 139-156.
59. Wilhelm P, Ritter U, Labbow S, Donhauser N, Röllinnghoff M, Bodgan C, Körner H 2001. Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF. J Immunol 166: 4012-4019.